Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Context-dependent cancer vulnerabilities: CRISPR screening under infl… Beta-Interferon · PMID 42496673 | Cancer | Neuroprotection · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies ar… | Cancer research 2026-08-16 13:04:48 | Source |
| Mitochondrial bioenergetic remodeling underlies fingolimod-induced im… Glatiramer acetate · PMID 42570637 | Sclérose en plaques | Remyélinisation indirecte / réparation · Ralentissement de la progression | Publication | PubMed | Voir la publication source Mitochondrial dysfunction and immune cell metabolic reprogramming are central mechanisms driving the pathogenesis and p… | Biomedicine & pharmacotherapy = Biomedecine & pharmaco… 2026-08-16 13:04:48 | Source |
| Short-term sodium-glucose cotransporter 2 inhibition with ipraglifloz… Beta-Interferon · PMID 42442614 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose by promoting urinary glucose excretion and also e… | Transplant immunology 2026-08-16 13:04:48 | Source |
| The diverse immunoregulatory role of iodine in thyropathy. Beta-Interferon · PMID 42434817 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Iodine is an environmental factor that contributes to the development of autoimmune thyroid diseases (AITDs). In this s… | Immunopharmacology and immunotoxicology 2026-08-16 13:04:48 | Source |
| B cell tolerance checkpoint function in multiple sclerosis and transi… Alemtuzumab GZ402673 · PMID 41505925 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Transient CD52 immune cell depletion with the monoclonal antibody alemtuzumab is highly effective in treating relapsing… | Journal of neuroimmunology 2026-08-16 13:04:47 | Source |
| Assessment and validation of the established free-running framework f… Ferumoxytol · PMID 42562162 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Cardiovascular magnetic resonance (CMR) is the reference standard for assessing cardiac function, yet its widespread cl… | Journal of cardiovascular magnetic resonance : officia… 2026-08-16 13:04:46 | Source |
| In-Depth optimization and characterization of prostatic and penile ve… Ferumoxytol · PMID 42482517 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Vasculogenic erectile dysfunction (ED) arises from impairment of the vascular supply to the penis and requires reliable… | Medical physics 2026-08-16 13:04:46 | Source |
| Targeting tumor‑associated macrophages in osteosarcoma: From molecula… Ferumoxytol · PMID 42285386 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source The clinical prognosis for osteosarcoma (OS) remains bottlenecked by chemoresistance and pulmonary metastasis. OS featu… | Pharmacological research 2026-08-16 13:04:46 | Source |
| Bioimaging of sense organs and the central nervous system in extant f… MRI contrast-enhancing preparations · PMID 39223842 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Bioimaging is changing the field of sensory biology, especially for taxa that are lesser-known, rare, and logistically… | Anatomical record (Hoboken, N.J. : 2007) 2026-08-16 13:04:45 | Source |
| Cerebral tuberculoma in pregnancy (Jan 1975-May 2025): a systematic r… MRI contrast-enhancing preparations · PMID 42316360 | Sclérose en plaques | Thérapie génique | Publication | PubMed | Voir la publication source Cerebral tuberculoma is an infrequent but life-threatening manifestation of tuberculosis whose diagnosis and treatment… | BMC infectious diseases 2026-08-16 13:04:45 | Source |
| GA Depot, a long-acting glatiramer acetate, vs placebo in patients wi… GA Depot · PMID 41705515 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source GA Depot is a long-acting glatiramer acetate (GA)-based formulation designed to provide significantly extended dosing i… | Multiple sclerosis (Houndmills, Basingstoke, England) 2026-08-16 13:04:42 | Source |
| The TRaditional versus Early Aggressive Therapy for Multiple Sclerosi… TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial · PMID 411… | Sclérose en plaques | Ralentissement de la progression · Traitement symptomatique | Publication | PubMed | Voir la publication source Whether early use of higher-efficacy disease-modifying therapy (DMT) reduces later risk of disability in multiple scler… | Contemporary clinical trials 2026-08-16 13:04:41 | Source |
| Greater activation of the "default" brain regions predicts stop signa… S103 cells · PMID 17884586 | Non communiqué | À vérifier | Publication | PubMed | Voir la publication source Previous studies have provided evidence for a role of the medial cortical brain regions in error processing and post-er… | NeuroImage 2026-08-16 13:04:36 | Source |
| Serial Cerebrospinal Fluid Sampling Reveals Trajectories of Potential… S103 cells · PMID 39121126 | Maladie d’Alzheimer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Synaptic dysfunction is closely associated with cognitive function in Alzheimer's disease (AD), and is present already… | Journal of Alzheimer's disease : JAD 2026-08-16 13:04:36 | Source |
| The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN)… S103 cells · PMID 39813774 | Non communiqué | Thérapie génique | Publication | PubMed | Voir la publication source Current treatments for acute myeloid leukemias (AMLs) cure fewer than 30 % of patients. This low efficacy is due, in pa… | European journal of medicinal chemistry 2026-08-16 13:04:36 | Source |
| A multicentre, prospective, randomized, open-label pragmatic trial to… CoQualSEP — Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scler… | Sclérose en plaques | Ralentissement de la progression · Traitement symptomatique | Publication | PubMed | Voir la publication source Paediatric-onset Multiple Sclerosis (POMS) is a rare, highly active disease requiring timely disease-modifying therapy.… | Neurological sciences : official journal of the Italia… 2026-08-16 13:04:35 | Source |
| Cognitive effects of transcranial random noise stimulation in schizop… transcranial direct current stimulation combined with cognitive training · PMID 42365849 | Sclérose en plaques | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Transcranial random noise stimulation (tRNS) has shown promising effects on working memory, attention, and learning in… | Journal of psychiatric research 2026-08-16 13:04:35 | Source |
| Cognitive Strategy-based neuromodulation optimizes neural communicati… transcranial direct current stimulation combined with cognitive training · PMID 42392337 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Rapid and effective enhancement of memory function through the integration of neuromodulation and cognitive training ha… | NeuroImage 2026-08-16 13:04:35 | Source |
| Functional near-infrared spectroscopy: Systematic mapping of abnormal… transcranial direct current stimulation combined with cognitive training · PMID 41495620 | Maladie de Parkinson · Sclérose latérale amyotrophique | À vérifier | Publication | PubMed | Voir la publication source Functional near-infrared spectroscopy quantifies cerebral hemodynamic signals by capturing oxygenation-dependent change… | Neural regeneration research 2026-08-16 13:04:35 | Source |
| The effects of fatigue, depression and the level of disability on the… CoQualSEP — Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scler… | Sclérose en plaques | Ralentissement de la progression · Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source The common symptoms of multiple sclerosis are fatigue, depression, cognitive dysfunction, pain and sexual dysfunction,… | Multiple sclerosis and related disorders 2026-08-16 13:04:35 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||